companiesCompany
GenFleet Therapeutics
aka 劢维医药
GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market.
Overview
Fulzerasib (GFH925, Dupert) approved August 2024; the KRAS G12C programme is partnered with Verastem in the US (VS-7375, formerly GFH375) and combination trials with cetuximab are running. Also KRAS G12D and RAS pan inhibitors in development.
Headquarters
Shanghai, CN
Scorecard
All companies#144of 680 companies, score 15
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 1 targets, 5 registry studies. Formula on the scorecards page.
Type
biotech
Website
Founded
2017
Pages like this
not linked directly; found by shared links- PersonMichael Yu (Yu De-Chao)
Shares Fulzerasib, Innovent Biologics and the tag china.
- CompanyIASO Biotherapeutics
Shares Innovent Biologics and the tag china.
- TrialORIENT-11
Shares Innovent Biologics and the tag china.
- TrialORIENT-16
Shares Innovent Biologics and the tag china.
- TrialFUMANBA-1
Shares Innovent Biologics and the tag china.
- TrialORIENT-32
Shares Innovent Biologics and the tag china.
- ProductEquecabtagene autoleucel
Shares Innovent Biologics and the tag china.
- ProductSintilimab
Shares Innovent Biologics and the tag china.